Journal of Neurochemistry 2013-08-01

Co-enzyme Q10 and idebenone use in Friedreich's ataxia.

Michael H Parkinson, Jörg B Schulz, Paola Giunti

Index: J. Neurochem. 126 Suppl 1 , 125-41, (2013)

Full Text: HTML

Abstract

Friedreich's ataxia is a debilitating progressive neurodegenerative disease associated with cardiomyopathy and other features. The underlying cause is a deficiency of the mitochondrial protein frataxin which causes mitochondrial iron deposition, increased oxidative stress and impaired adenosine triphosphate production. Over the last 15 years, multiple clinical trials have assessed the efficacy of antioxidant agents in this disease. This article reviews trials of the two most important agents, namely co-enzyme Q10 and idebenone.© 2013 International Society for Neurochemistry.

Related Compounds

  • Idebenone

Related Articles:

2-deoxy-D-glucose enhances anesthetic effects in mice.

2015-02-01

[Anesth. Analg. 120(2) , 312-9, (2015)]

Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

1994-08-01

[Drugs Aging 5(2) , 133-52, (1994)]

Idebenone: an emerging therapy for Friedreich ataxia.

2009-03-01

[J. Neurol. 256 Suppl 1 , 25-30, (2009)]

Pharmacokinetic evaluation of idebenone.

2010-11-01

[Expert Opin. Drug Metab. Toxicol. 6(11) , 1437-44, (2010)]

[The use of idebenone (noben) in neurological practice].

2006-01-01

[Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 106(11) , 66-71, (2006)]

More Articles...